Pinatuzumab vedotin

Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575) . Pinatuzumab vedotin has antitumor activities[1].

Product Specifications

CAS Number

[1313706-14-7]

Product Name Alternative

Anti-CD22-vc-MMAE; DCDT2980S

UNSPSC

12352211

Target

Antibody-Drug Conjugates (ADCs) ; CD22; Microtubule/Tubulin

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

98.25

Smiles

[Pinatuzumabvedotin]

References & Citations

[1]Ranjana H Advani, et al. Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Trial Clin Cancer Res. 2017 Mar 1;23 (5) :1167-1176.|[2]Yip, V., et al., (2024) . Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species. Xenobiotica; the fate of foreign compounds in biological systems, 54 (8), 511–520.